| Nevro is a medical device company focused on delivering solutions for patient with pain treatment. Co. has developed and commercialized the Senza® spinal cord stimulation (SCS) system, a neuromodulation platform for the treatment of chronic pain, with the Senza® Omnia platform being an addition to the Senza family of products. Co.'s proprietary, paresthesia-free 10 kHz Therapy, delivered by its Senza system is designed to treat back pain and leg pain. In addition, Co. received approval of unilateral or bilateral pain, associated with painful diabetic neuropathy and expanded labeling in non-surgical refractory back pain. We show 39 historical shares outstanding datapoints in our coverage of NVRO's shares outstanding history.
Understanding the changing numbers of NVRO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NVRO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NVRO by allowing them to research NVRO shares outstanding history
as well as any other stock in our coverage universe.